• 1
    Kragh-Hansen U, Chuang VTG, Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharmacol Bull 2002; 25: 695704.
  • 2
    Bertucci C, Domenici E. Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Curr Med Chem 2002; 9: 14631481.
  • 3
    Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett 2008; 582: 17831787.
  • 4
    Palesch YY, Hill MD, Ryckborst KJ, Tamarz D, Ginsberg MD. The ALIAS pilot trial. A dose escalation and safety study of albumin therapy for acute ischemic stroke—II: Neurologic outcome and efficacy analysis. Stroke 2006; 37: 21072114.
  • 5
    Milojevic J, Esposito V, Das R, Melacini G. Understanding the molecular basis for the inhibition of the Alzheimer's Abeta-peptide oligomerization by human serum albumin using saturation transfer difference and off-resonance relaxation NMR spectroscopy. J Am Chem Soc 2007; 129: 42824290.
  • 6
    Gurachevsky A, Kazmierczak SC, Jörres A, Muravsky V. Application of spin label paramagnetic resonance in the diagnosis and prognosis of cancer and sepsis. Clin Chem Lab Med 2008; 46: 12031210.
  • 7
    Faure P, Wiernsperger N, Polge C, Favier A, Halimi S. Impairment of antioxidant properties of serum albumin in diabetic patients: protective effects of metformin. Clin Sci (London) 2008; 114: 251256.
  • 8
    Oettl K, Stauber RE. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 2007; 151: 580590.
  • 9
    Anraku M, Yamasaki K, Maruyama T, Kragh-Hansen U, Otagiri M. Effect of oxidative stress on the structure and function of human serum albumin. Pharm Res 2001; 18: 632639.
  • 10
    Jalan R, Kerstin S, Mookerjee R, Sen S, Lisa C, Stephen H, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis are associated with increased mortality. HEPATOLOGY 2009.
  • 11
    Halliwell B, Gutteridge JM. The antioxidants of human extracellular fluids. Arch Biochem Biophys 1990; 280: 18.
  • 12
    Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008; 28: 8195.
  • 13
    Gines P, Tito L, Arroyo V, Planas R, Panes J, Viver J, et al. Randomized comparative study of therapeutic paracentesis with and without albumin in cirrhosis. Gastroenterology 1988; 94: 14941502.
  • 14
    Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 114: 10021010.
  • 15
    Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403409.
  • 16
    Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De-las-Heras D, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective nonrandomized study. HEPATOLOGY 2002; 36: 941948.
  • 17
    Fernandez J, Navasa M, Garcia-Pagan JC, G-Abraldes J, Jimenez W, Bosch J, et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol 2004; 41: 384390.
  • 18
    Fernadez J, Monteagudo J, Bargallo X, Jimenez W, Bosch J, Arroyo V, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. HEPATOLOGY 2005; 42: 627634.
  • 19
    Hassanein TI, Toften F, Brown RS Jr, McGuire B, Lynch P, Mehta R, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. HEPATOLOGY 2007; 46: 18531862.
  • 20
    Saliba F, Camus C, Durand F, Mathurin P, Delafosse B, Baranque K, et al. Randomized controlled multicenter trial evaluating the efficacy and safety of albumin dialysis with MARS in patients with fulminant and subfulminant hepatic failure [Abstract]. HEPATOLOGY 2008; 48( Suppl): 377A.